The Valley Desk

ArticleCancer medicinePublished

Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Cancer medicine
Published
Subject terms
Humans; Piperidines; Adenine; Protein Kinase Inhibitors; Aged; Medicare; United States; Leukemia, Lymphocytic, Chronic, B-Cell; Elderly; Chronic Lymphocytic Leukemia; Discontinuation; Adverse Event
PubMed ID
38348963
PubMed Central ID
PMC10832339
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal